Skadden advised Vertex Pharmaceuticals Incorporated on the deal while Cooley represented ViaCyte. Vertex Pharmaceuticals Incorporated (“Vertex”) has entered into a definitive agreement under which Vertex will acquire...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here